A 28-year-old man with a history of Graves disease treated with antithyroid drugs 2 years ago now presents with palpitations, tremor, and heat intolerance. TSH is suppressed at 0.1 mIU/L (normal 0.4–4.0), and free T4 is elevated at 22 ng/dL (normal 7–18). Which investigation is most specific for determining whether he has relapsed Graves disease or developed thyroiditis?

Explanation

## Distinguishing Graves Disease Relapse from Thyroiditis **Key Point:** TSH receptor antibodies (TRAb) or thyroid-stimulating immunoglobulin (TSI) are the most specific investigations to confirm active Graves disease and distinguish it from thyroiditis, which presents with similar biochemical findings (suppressed TSH, elevated free T4) but different pathophysiology. ### Clinical Context: Relapse vs. Thyroiditis Both conditions present with: - Suppressed TSH - Elevated free T4 - Hyperthyroid symptoms However, the underlying mechanism differs: | Feature | Graves Disease (Relapse) | Thyroiditis | | --- | --- | --- | | **Pathophysiology** | TSH receptor antibodies stimulate thyroid | Inflammation releases preformed hormone | | **Antibody present** | TSI/TRAb positive | TPO/thyroglobulin antibodies (may be positive) | | **Radioiodine uptake** | High (stimulated gland) | Low (inflamed, not synthesizing) | | **Treatment** | Antithyroid drugs, beta-blockers, radioiodine, surgery | Beta-blockers, NSAIDs, corticosteroids if severe | | **Prognosis** | Chronic, relapsing | Self-limited (weeks to months) | ### Why TSI/TRAb is Most Specific **High-Yield:** TSI and TRAb directly measure the pathogenic antibodies that cause Graves disease by binding to and activating the TSH receptor. Their presence confirms active Graves disease and rules out thyroiditis. ```mermaid flowchart TD A[Suppressed TSH + High Free T4]:::outcome --> B[Measure TSI/TRAb]:::action B --> C{TSI/TRAb Positive?}:::decision C -->|Yes| D[Graves Disease Relapse]:::outcome C -->|No| E[Likely Thyroiditis]:::outcome D --> F[Antithyroid drugs or radioiodine]:::action E --> G[Beta-blockers, NSAIDs, supportive care]:::action ``` ### Diagnostic Specificity Comparison | Investigation | Sensitivity for Graves | Specificity for Graves | Utility | | --- | --- | --- | --- | | **TSI/TRAb** | 85–90% | >95% | **Gold standard** — directly identifies pathogenic antibodies | | **TPO antibodies** | 50% | Low | Non-specific; present in Hashimoto and other autoimmune thyroid disease | | **Thyroid ultrasound** | Moderate | Low | Shows echogenicity changes but overlaps with thyroiditis | | **Radioiodine uptake** | High | High | Excellent but invasive; high uptake = Graves, low = thyroiditis | **Clinical Pearl:** In a patient with known Graves disease history, TSI/TRAb positivity confirms relapse, whereas negativity suggests thyroiditis (post-treatment, silent, or de Quervain thyroiditis). This distinction is critical because antithyroid drugs are ineffective in thyroiditis. **Mnemonic:** **TRAb = Thyroid Receptor Antibody** — the specific antibody that causes Graves disease by mimicking TSH and stimulating the thyroid receptor. [cite:Harrison 21e Ch 405]